Shots:
- Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones
- Novo Nordisk acquires Prothena’s subsidiary and gets WW rights to the IP and related rights of Prothena’s ATTR amyloidosis business and pipeline. Novo Nordisk will develop the P-II ready Ab PRX004 for ATTR cardiomyopathy
- Prothena has completed a P-I study of PRX004 in patients with hereditary forms of ATTR which showed that the therapy was safe and well tolerated
Click here to read full press release/ article | Ref: Prothena | Image: Tip Ranks
The post Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B first appeared on PharmaShots.
